J. Jubrail (Edinburgh, United Kingdom), A. Huerta Garcia (Barcelona, Spain), F. Schleich (Liège, Belgium), J. Allinson (London, United Kingdom)
Efficiency of different approaches for the assessment of the risk of exacerbations in patients with COPD
A. Corlateanu (Chisinau, Republic of Moldova), E. Scutaru (Chisinau, Republic of Moldova), D. Rusu (Chisinau, Republic of Moldova), O. Corlateanu (Chisinau, Republic of Moldova), S. Covantsev (Chisinau, Republic of Moldova), V. Botnaru (Chisinau, Republic of Moldova)
|   |
Factors associated with prolonged duration of AECOPD:Analysis of the ECLIPSE cohort
M. Fahey (London, United Kingdom), W. Meeraus (London, United Kingdom), C. El Baou (London, United Kingdom), H. Mullerova (London, United Kingdom), E. M. Hessel (London, United Kingdom), W. A. Fahy (London, United Kingdom)
| |
Inappropriate Utilization of Antibiotics in COPD Exacerbations
Y. Varol (Izmir, Turkey), Z. Karakurt (Istanbul, Turkey), A. Cirak (Izmir, Turkey), H. Sahin (Izmir, Turkey), C. Kirakli (Izmir, Turkey), B. Komurcuoglu (Izmir, Turkey)
| |
Identification of risk factors of acute cardiovascular events in acute exacerbation period for patients with COPD: a prospective nested case-control study
W. Hu (Shanghai, China), T. Lhamo (Shanghai, China), Y. Zuo (Shanghai, China), Y. Zeng (Shanghai, China), J. Zhang (Shanghai, China)
| |
Outcomes among admitted and outpatient RSV adult patients with chronic obstructive pulmonary disease
S. Bolge (Raritan, NJ, United States of America), V. Wyffels (Beerse, Belgium), F. Kariburyo (Ann Arbor, MI, United States of America), H. Yuce (New York, NY, United States of America), R. Fleischhackl (Vienna, Austria)
| |
Cardiac troponin increases in COPD patients hospitalised for pneumonias as well as exacerbations
V. Søyseth (Lorenskog, Norway), N. Kononova (Lorenskog, Norway), G. Einvik (Lorenskog, Norway)
| |
Predictors for early readmission after COPD exacerbation
I. Bocigas (Valencia, Spain), A. Mulet (Valencia, Spain), C. Lahosa (Valencia, Spain), J. Signes-Costa Miñana (Valencia, Spain), B. Safont (Valencia, Spain), C. Gonzalez (Valencia, Spain), E. Servera (Valencia, Spain)
| |
frequent exacerbations of COPD are associated with severity of airflow limitation and chronic cough, sputum production.
k. karim (algiers, Algeria), S. Taright (algiers, Algeria), A. Fissah (algiers, Algeria)
| |
COPD self-management exacerbation action plans: predictors of adherence
J. Schrijver (Enschede, Netherlands), T. Effing (Adelaide, Australia), M. Brusse-Keizer (Enschede, Netherlands), J. Van Der Palen (Enschede, Netherlands), P. Van Der Valk (Enschede, Netherlands), A. Lenferink (Enschede, Netherlands)
| |
Cardiac biomarkers and outcomes of COPD exacerbations
E. Shafuddin (Hamilton, New Zealand), C. Chang (Hamilton, New Zealand), R. Hancox (Dunedin, New Zealand)
| |
Predicting treatment outcomes following an exacerbation of airways disease
A. Halner (Oxford, United Kingdom), S. Beer (Oxford, United Kingdom), M. Bafadhel (Oxford, United Kingdom), R. Russell (Oxford, United Kingdom)
| |
Clinical analysis of acute exacerbation of COPD cases with increased eosinophilic granulocytes in peripheral blood
T. Ma (Changchun, China), Y. Hu (Changchun, China), Q. Zhang (Changchun, China)
| |
The importance of C-reactive protein in patients with acute exacerbation of severe COPD
I. Savelikhina (Ivano-Frankivsk, Ukraine), K. Ostrovska (Ivano-Frankivsk, Ukraine), O. Varunkiv (Ivano-Frankivsk, Ukraine), M. Ostrovskyy (Ivano-Frankivsk, Ukraine), K. Shvets (Ivano-Frankivsk, Ukraine), N. Korzh (Ivano-Frankivsk, Ukraine)
| |
Outcomes of patients with hypoxemia referred to the home oxygen service post-acute exacerbation of chronic lung disease
A. Mowat (Stoke on Trent, United Kingdom), M. Marathe (Stoke on Trent, United Kingdom), A. Ali (Stoke on Trent, United Kingdom), N. Tran (Stoke on Trent, United Kingdom), K. Leech (Stoke on Trent, United Kingdom), V. Campbell (Stoke on Trent, United Kingdom), N. Mustfa (Stoke on Trent, United Kingdom)
| |
FEV1/FEV6 index in hospitalized patients with multimorbidity
B. Garcia Cabo (Barcelona, Spain), K. Shakeel (Barcelona, Spain), L. Simon (Barcelona, Spain), A. Navarro Rolon (Barcelona, Spain), P. Almagro Mena (Barcelona, Spain)
| |
The Impact of Multimorbidity on Hospitalizations in Patients with Chronic Obstructive Pulmonary Disease (COPD): a Population-Based Study
E. Jureviciene (Vilnius, Lithuania), R. Puronaite (Vilnius, Lithuania), E. Danila (Vilnius, Lithuania)
| |
Study of clinical presentation and predictors of adverse outcome in patients admitted for acute exacerbation of COPD.
P. Maheshwari (KOLKATA, India)
| |
What are the differences between moderate and severe COPD exacerbation groups?
F. Çiftci (Ankara, Turkey), D. Dogan Mülazimoglu (Ankara, Turkey), S. Ayöz (Ankara, Turkey), B. Atasoy (Ankara, Turkey), E. Sen (Ankara, Turkey)
| |
Characteristics of patients with frequent EXACT-PRO defined exacerbations
A. Yousuf (Leicester, United Kingdom), G. Parekh (Bedford, United Kingdom), J. Finch (Leicester, United Kingdom), S. Parker (Leicester, United Kingdom), S. Glover (Leicester, United Kingdom), L. Carr (Leicester, United Kingdom), A. Duvoix (Bedford, United Kingdom), V. Mistry (Leicester, United Kingdom), L. O'Brien (Cardiff, United Kingdom), K. Lewis (Swansea, United Kingdom), C. Brightling (Leicester, United Kingdom)
| |
Identifying tools to investigate outcomes following an exacerbation of COPD
P. Burrage (Brisbane, Australia), A. Halner (Oxford, United Kingdom), D. Nicolau (Brisbane, Australia), M. Bafadhel (Oxford, United Kingdom)
| |